Amifampridine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319928

CAS#: 54-96-6 (free base)

Description: Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The phosphate salt of amifampridine is a more stable formulation that does not require refrigeration. In the United States, amifampridine is under investigation for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Amifampridine is also used to treat many of the congenital myasthenic syndromes, particularly those with defects in choline acetyltransferase, downstream kinase 7, and those where any kind of defect causes "fast channel" behaviour of the acetylcholine receptor.


Chemical Structure

img
Amifampridine
CAS# 54-96-6 (free base)

Theoretical Analysis

MedKoo Cat#: 319928
Name: Amifampridine
CAS#: 54-96-6 (free base)
Chemical Formula: C5H7N3
Exact Mass: 109.06
Molecular Weight: 109.132
Elemental Analysis: C, 55.03; H, 6.47; N, 38.50

Price and Availability

Size Price Availability Quantity
1g USD 150 2 Weeks
2g USD 250 2 Weeks
5g USD 550 2 Weeks
10g USD 850 2 Weeks
20g USD 1450 2 Weeks
100g USD 2950 2 Weeks
Bulk inquiry

Related CAS #: 54-96-6 (free base)   446254-47-3 (phosphate)    

Synonym: 3,6-DAP; BRN-0110232; BRN 0110232; BRN0110232; NSC 521760; SC10; Amifampridine; Firdapse.

IUPAC/Chemical Name: 3,4-Diaminopyridine

InChi Key: OYTKINVCDFNREN-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H7N3/c6-4-1-2-8-3-5(4)7/h1-3H,7H2,(H2,6,8)

SMILES Code: NC1=C(N)C=NC=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related: 54-96-6 (Amifampridine free base) 446254-47-3 (Amifampridine phosphate).

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 109.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Oh SJ, Shcherbakova N, Kostera-Pruszczyk A, Alsharabati M, Dimachkie M, Blanco JM, Brannagan T, Lavrnić D, Shieh P, Vial C, Meisel A, Komoly S, Schoser B, Sivakumar K, So Y; LEMS Study Group. Amifampridine phosphate (Firdapse®) is Effective and Safe in A Phase 3 Clinical Trial in LEMS. Muscle Nerve. 2016 Feb 6. doi: 10.1002/mus.25070. [Epub ahead of print] PubMed PMID: 26852139.

2: Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther. 2015 Dec;4(2):105-24. doi: 10.1007/s40120-015-0034-0. Epub 2015 Nov 2. PubMed PMID: 26525537; PubMed Central PMCID: PMC4685864.

3: Haroldsen PE, Musson DG, Hanson B, Quartel A, O'Neill CA. Effects of Food Intake on the Relative Bioavailability of Amifampridine Phosphate Salt in Healthy Adults. Clin Ther. 2015 Jul 1;37(7):1555-63. doi: 10.1016/j.clinthera.2015.05.498. Epub 2015 Jun 20. PubMed PMID: 26101174.

4: Haroldsen PE, Garovoy MR, Musson DG, Zhou H, Tsuruda L, Hanson B, O'Neill CA. Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099. doi: 10.1002/prp2.99. Epub 2014 Dec 9. PubMed PMID: 25692017; PubMed Central PMCID: PMC4317230.

5: Dooms M, Pincé H, Simoens S. Do we need authorized orphan drugs when compounded medications are available? J Clin Pharm Ther. 2013 Feb;38(1):1-2. doi: 10.1111/jcpt.12006. Epub 2012 Sep 14. PubMed PMID: 22973866.

6: Sedehizadeh S, Keogh M, Maddison P. The use of aminopyridines in neurological disorders. Clin Neuropharmacol. 2012 Jul-Aug;35(4):191-200. doi: 10.1097/WNF.0b013e31825a68c5. Review. PubMed PMID: 22805230.

7: Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat. 2011;7:341-9. doi: 10.2147/NDT.S10464. Epub 2011 May 30. PubMed PMID: 21822385; PubMed Central PMCID: PMC3148925.

8: Green DM, Jones AC, Brain KR. Content variability of active drug substance in compounded oral 3,4-diaminopyridine products. J Clin Pharm Ther. 2012 Feb;37(1):53-7. doi: 10.1111/j.1365-2710.2011.01249.x. Epub 2011 Apr 19. PubMed PMID: 21501202.